Anil Potti

Anil Potti
Name	Anil Potti
Birth date	1970s
Birth place	India
Occupation	Oncologist, former researcher
Alma mater	Mayo Clinic College of Medicine and Science, Duke University School of Medicine
Known for	Gene-expression signature research, clinical trials controversy

Anil Potti is an Indian-born physician and former cancer researcher whose work on genomic predictors of chemotherapy response drew attention and later retraction. He held positions at Duke University and collaborated with investigators at institutions including the National Cancer Institute, the Mayo Clinic, and biotechnology firms before his research was challenged. The case involved scientific journals such as Nature Medicine, The New England Journal of Medicine, and Lancet Oncology, and triggered inquiries by bodies including the Office of Research Integrity and state courts.

Early life and education

Potti was born in India and completed medical training that led him to pursue postgraduate study in the United States. He undertook residency and fellowship training at institutions including Mayo Clinic and completed oncology training at Duke University School of Medicine. During this period he engaged with investigators from the National Institutes of Health, collaborators from Harvard Medical School, and faculty connected to programs at Johns Hopkins University and University of Pennsylvania.

Academic and clinical career

Potti joined the faculty of Duke University as a clinician-researcher in thoracic oncology and experimental therapeutics, working with teams that included faculty from Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and the Vanderbilt-Ingram Cancer Center. He was involved in translational research bridging molecular profiling platforms produced by vendors linked to Affymetrix, academic cores at Broad Institute, and cooperative group networks such as the Eastern Cooperative Oncology Group. Potti also interacted with pharmaceutical partners including Eli Lilly and Company and Genentech in designing trials evaluating chemotherapeutic regimens.

Research contributions and publications

Potti published papers claiming that gene-expression signatures could predict sensitivity to specific chemotherapies, reporting results in journals like Nature Medicine and Proceedings of the National Academy of Sciences. His work referenced genomic datasets generated with platforms from Affymetrix and analytical methods associated with groups at the Broad Institute, Stanford University School of Medicine, and MIT. Collaborators listed co-authors from institutions such as Mayo Clinic, University of North Carolina at Chapel Hill, and Ohio State University. The studies purported to connect tumor biology characterized by gene-expression profiles to drug response for agents including cisplatin, paclitaxel, and experimental targeted therapies developed by firms such as Pfizer and Roche.

Controversies and misconduct investigation

Questions arose when statisticians and bioinformaticians at organizations including MD Anderson Cancer Center, Harvard Medical School, and independent groups reanalyzed published data and alleged errors and misrepresentations. Critiques published in forums involving researchers from Brigham and Women's Hospital, University of California, San Francisco, and members of the International Committee of Medical Journal Editors highlighted irregularities in datasets and code. Journals including Nature Medicine, Cancer Cell, and Journal of Clinical Oncology published corrections and retractions. Institutional investigations were undertaken by Duke University and the Office of Research Integrity, while clinical trial oversight involved the Food and Drug Administration and cooperative groups such as the National Cancer Institute's clinical trials programs. The controversy attracted attention from media organizations including The New York Times, The Wall Street Journal, and Science.

Legal actions and institutional responses

Legal responses included litigation involving plaintiffs represented by law firms active in medical-legal matters, filings in North Carolina state courts, and settlement negotiations implicating insurers and institutions like Duke University Medical Center. Academic responses included faculty hearings, resignations, and policy reviews influenced by standards from the Association of American Medical Colleges, American Association for the Advancement of Science, and guidance from the Office of Research Integrity. Journals issued retractions and expressions of concern under procedures aligned with the Committee on Publication Ethics.

Later career and current status

Following institutional actions, Potti resigned from his positions and pursued activities outside mainstream academic oncology, including roles at clinics and private practices interconnected with regional medical centers. Subsequent employment and licensing matters involved state medical boards such as the North Carolina Medical Board and credentialing entities at hospitals including Durham Regional Hospital and community oncology practices. The long-term consequences of the controversy influenced policy debates at institutions like Duke University, regulatory bodies including the Food and Drug Administration, and research-funding agencies such as the National Institutes of Health.

Category:Medical controversies Category:Oncologists Category:Scientists from India